2019-027 SMALL MOLECULE DRUGS ACCELERATE IMPLANT OSSEOINTEGRATION

INTRODUCTION:

UCLA researchers at the School of Dentistry have elucidated the molecular mechanism of osseointegration, and identified Npas2 modulating compounds that can be used to enhance implant osseointegration.

 

BACKGROUND:

The biologically inert property of titanium (Ti) and Ti alloy makes Ti-based biomaterials widely adopted in implantable medical devices for orthopedic and dental applications. Ti-based biomaterials induce the least foreign body reaction, minimal fibrosis, and allow osseointegration without a layer of soft tissue encapsulation. Surface functionalized Ti implants have been shown to improve and accelerate the osseointegration process, although the underlying mechanisms are not fully understood.

 

INNOVATION:       

Researchers at UCLA have identified that the molecular circadian clock gene neuronal PAS domain protein 2 (Npas2) plays an important role in the establishment of osseointegration induced by Ti biomaterials with a complex surface modification. These researchers have also identified Npas2 upregulating small molecule compounds that hold promise for accelerating and/or re-establishing the implant osseointegration.

 

POTENTIAL APPLICATIONS:

•       Implant osseointegration for orthopedic and dental applications

 

ADVANTAGES:

•       Enhance implant osseointegration

 

DEVELOPMENT-TO-DATE:

Several Npas2 upregulating small molecules have been tested in vitro.

Patent Information:
For More Information:
Earl Weinstein
Associate Director of Business Development
eweinstein@tdg.ucla.edu
Inventors:
Ichiro Nishimura
Akishige Hokugo
Kenzo Morinaga
Hodaka Sasaki